Wuxi

Speed is a critical factor in early-stage development. Solid state studies within an integrated CMC platform can support formulation development, accelerate timelines to Phase I clinical studies and increase the likelihood of successful clinical trial results.

WuXi Sta outlines clear guidance on phase appropriate RSM designation and adaptive RSM strategy for the overall API development roadmap. These solutions will mitigate both quality and regulatory risks, thus increasing the chance of success in IND and NDA filing.

Webinar Date/Time: Mon, Dec 12, 2022 11:00 AM EST

Tuesday, June 29, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST